Update shared on05 Sep 2025
Fair value Increased 4.22%Neuland Laboratories’ target price has been revised upward as a result of a marked increase in its forecast P/E ratio despite a significant decline in net profit margin, now reflecting a new consensus of ₹16,375.
What's in the News
- Special/Extraordinary Shareholders Meeting to be conducted via postal ballot.
- Board meeting scheduled to approve and record unaudited financial results for the quarter ended June 30, 2025.
Valuation Changes
Summary of Valuation Changes for Neuland Laboratories
- The Consensus Analyst Price Target has risen slightly from ₹15712 to ₹16375.
- The Future P/E for Neuland Laboratories has significantly risen from 30.90x to 40.16x.
- The Net Profit Margin for Neuland Laboratories has significantly fallen from 27.95% to 23.33%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.